Phreesia saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 89 to 92.
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the best stocks tend to have an RS Rating of over 80 as they launch their biggest price moves.
Here Are 3 Keys For Successful Stock Investing
Phreesia has risen more than 5% past a 26.45 entry in a first-stage double bottom, meaning it's now out of a proper buy range. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Phreesia posted 0% earnings growth last quarter, while sales growth came in at 15%.
The company earns the No. 5 rank among its peers in the Computer Software-Medical industry group. Doximity is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
